Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/II open-label multicenter study of intravenous Olvi-Vec followed by platinum plus etoposide in platinum-relapsed or platinum-refractory advanced small cell lung cancer
CTR20223399Phase 2Active
- Sponsor
- Genelux Corporation
- Start
- Apr 2023
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics, Gene Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of olvimulogene nanivacirepvec in small cell lung cancer (SCLC), sponsored by Genelux Corporation. Primary endpoints: Safety and tolerability and Objective response rate. Started Apr 2023; status: active.
02
Drugs
olvimulogene nanivacirepvec
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on CTR20223399.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20223399.